664. Are Thousands of Medical Cures Hiding in Plain Sight? - Freakonomics Radio Recap
Podcast: Freakonomics Radio
Published: 2026-02-20
Duration: 52 min
Summary
The episode explores the potential of repurposing approved drugs to treat diseases that currently lack effective treatments, showcasing the story of balamuthia and its treatment with nitroxyline as a case study. It raises important questions about the hidden medical cures that might be just out of reach due to regulatory hurdles.
What Happened
The episode begins with Heather Stone, a health science policy analyst at the FDA, discussing an obscure but deadly disease called balamuthia, known as a brain-eating amoeba. This disease is exceedingly rare and has no FDA-approved treatments, yet a case in San Francisco showed promise when a clinician used nitroxyline, a drug traditionally used for urinary tract infections, resulting in a remarkable recovery for one patient. This unexpected treatment raises questions about the current understanding of drug efficacy and the potential for existing medications to be used in novel ways.
The narrative shifts to David Fegenbaum, who shares his personal journey from aspiring college quarterback to a physician-scientist at the University of Pennsylvania after his mother's battle with brain cancer. His experience with a rare disease, Castleman's disease, during medical school highlighted the challenges in treating illnesses with no existing solutions. David's story underscores a fundamental issue in healthcare: there are over 18,000 known human diseases, yet only a fraction have FDA-approved treatments. This episode serves as a call to action to explore the vast potential of repurposing existing drugs to save lives.
Key Insights
- Balamuthia is a rare and deadly disease with no FDA-approved treatments.
- Nitroxyline, a drug for urinary tract infections, demonstrated unexpected effectiveness against balamuthia.
- Only about a quarter of known diseases have approved treatments, indicating a vast area for potential medical discovery.
- Personal stories like David Fegenbaum's highlight the urgent need for innovative approaches in treating rare diseases.